MYD88 Mutations Predict Unfavorable Prognosis in Chronic Lymphocytic Leukemia Patients with Mutated IGHV Gene

Overview

Journal Blood Cancer J

Date 2017 Dec 16

PMID 29242635

Citations 13

Authors

Shu-Chao Qin

Yi Xia

Yi Miao

Hua-Yuan Zhu

Jia-Zhu Wu

Lei Fan

Jian-Yong Li

Wei Xu

Chun Qiao

Affiliations

Soon will be listed here.

Citing Articles

NF-ΚB Activation as a Key Driver in Chronic Lymphocytic Leukemia Evolution to Richter's Syndrome: Unraveling the Influence of Immune Microenvironment Dynamics.

Rohan P, Binato R, Abdelhay E Genes (Basel). 2024; 15(11).

PMID: 39596634 PMC: 11593636. DOI: 10.3390/genes15111434.

[Current status of diagnosis and treatment of chronic lymphocytic leukemia in China: A national multicenter survey research].

Xu W, Yi S, Feng R, Wang X, Jin J, Mi J Zhonghua Xue Ye Xue Za Zhi. 2023; 44(5):380-387.

PMID: 37550187 PMC: 10440613. DOI: 10.3760/cma.j.issn.0253-2727.2023.05.005.

NF-kB and the CLL microenvironment.

ODonnell A, Pepper C, Mitchell S, Pepper A Front Oncol. 2023; 13:1169397.

PMID: 37064123 PMC: 10098180. DOI: 10.3389/fonc.2023.1169397.

-Mutated Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma as a Distinctive Molecular Subgroup Is Associated with Atypical Immunophenotypes in Chinese Patients.

Mu Y, Fan X, Chen T, Meng Y, Lin J, Yuan J J Clin Med. 2023; 12(7).

PMID: 37048750 PMC: 10094974. DOI: 10.3390/jcm12072667.

Genetic and Clinical Characteristics of Korean Chronic Lymphocytic Leukemia Patients with High Frequencies of Mutations.

Ahn A, Kim H, Kim T, Lee J, Kang D, Yu H Int J Mol Sci. 2023; 24(4).

PMID: 36834590 PMC: 9959581. DOI: 10.3390/ijms24043177.

References

Ngo V, Young R, Schmitz R, Jhavar S, Xiao W, Lim K . Oncogenically active MYD88 mutations in human lymphoma. Nature. 2010; 470(7332):115-9. PMC: 5024568. DOI: 10.1038/nature09671. View

Puente X, Pinyol M, Quesada V, Conde L, Ordonez G, Villamor N . Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011; 475(7354):101-5. PMC: 3322590. DOI: 10.1038/nature10113. View

Staiger A, Ott M, Parmentier S, Rosenwald A, Ott G, Horn H . Allele-specific PCR is a powerful tool for the detection of the MYD88 L265P mutation in diffuse large B cell lymphoma and decalcified bone marrow samples. Br J Haematol. 2015; 171(1):145-8. DOI: 10.1111/bjh.13369. View

Xu L, Hunter Z, Yang G, Zhou Y, Cao Y, Liu X . MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013; 121(11):2051-8. PMC: 3596964. DOI: 10.1182/blood-2012-09-454355. View

Varettoni M, Arcaini L, Zibellini S, Boveri E, Rattotti S, Riboni R . Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms. Blood. 2013; 121(13):2522-8. DOI: 10.1182/blood-2012-09-457101. View

Jeromin S, Weissmann S, Haferlach C, Dicker F, Bayer K, Grossmann V . SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. Leukemia. 2013; 28(1):108-17. DOI: 10.1038/leu.2013.263. View

Baliakas P, Hadzidimitriou A, Agathangelidis A, Rossi D, Sutton L, Kminkova J . Prognostic relevance of MYD88 mutations in CLL: the jury is still out. Blood. 2015; 126(8):1043-4. PMC: 4598193. DOI: 10.1182/blood-2015-05-648634. View

Hallek M, Cheson B, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H . Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008; 111(12):5446-56. PMC: 2972576. DOI: 10.1182/blood-2007-06-093906. View

Cao X, Ye Q, Orlowski R, Wang X, Loghavi S, Tu M . Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. J Hematol Oncol. 2015; 8:74. PMC: 4487966. DOI: 10.1186/s13045-015-0172-y. View

10.

Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M . Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26 Suppl 5:v78-84. DOI: 10.1093/annonc/mdv303. View

11.

Cortese D, Sutton L, Cahill N, Smedby K, Geisler C, Gunnarsson R . On the way towards a 'CLL prognostic index': focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort. Leukemia. 2013; 28(3):710-3. DOI: 10.1038/leu.2013.333. View

12.

Martinez-Trillos A, Pinyol M, Navarro A, Aymerich M, Jares P, Juan M . Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome. Blood. 2014; 123(24):3790-6. DOI: 10.1182/blood-2013-12-543306. View

13.

Muzio M, Scielzo C, Bertilaccio M, Frenquelli M, Ghia P, Caligaris-Cappio F . Expression and function of toll like receptors in chronic lymphocytic leukaemia cells. Br J Haematol. 2008; 144(4):507-16. DOI: 10.1111/j.1365-2141.2008.07475.x. View

14.

Miao Y, Fan L, Wu Y, Xia Y, Qiao C, Wang Y . Low expression of CD200 predicts shorter time-to-treatment in chronic lymphocytic leukemia. Oncotarget. 2016; 7(12):13551-62. PMC: 4924660. DOI: 10.18632/oncotarget.6948. View

15.

Baliakas P, Hadzidimitriou A, Sutton L, Rossi D, Minga E, Villamor N . Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia. 2014; 29(2):329-36. DOI: 10.1038/leu.2014.196. View

16.

Xia Y, Fan L, Wang L, Gale R, Wang M, Tian T . Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans. Oncotarget. 2015; 6(7):5426-34. PMC: 4467158. DOI: 10.18632/oncotarget.3101. View